29 results about "Recombinant GH" patented technology

The invention relates to the technical field of biological medicine, in particular to polypeptide for promoting release of growth hormone and application of the polypeptide, the polypeptide is shown as a formula (I), and in addition, the invention further provides application of the polypeptide shown as the formula (I) in preparation of medicine for diagnosing and / or treating diseases related to human growth hormone deficiency. Formula (I)

The present disclosure relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and their use in treating growth hormone deficiency or a condition associated with an abnormal reduction in growth hormone (GH) secretion in a subject that has adequate GH secretion potential.

The present disclosure relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and their use in treating growth hormone deficiency or a condition associated with an abnormal reduction in growth hormone (GH) secretion in a subject that has adequate GH secretion potential.

The application discloses a method for preparing GHR humanized animal cells by using a CRISPR system, which comprises the following steps: designing and synthesizing sgRNA; mixing the sgRNA with a Cas9 protein to form a CRISPR-Cas9 complex; constructing donor DNA containing coding sequences of a human GHR extracellular region and a rat GHR intracellular region; injecting the CRISPR-Cas9 complex and the donor DNA into the cytoplasm or nucleus of a rat fertilized ovum to knockout the coding sequence of the extracellular region of the rat-derived GHR gene and simultaneously insert the coding sequence of the extracellular region of the human-derived GHR gene into the genome, so that the GHR humanized animal cells are obtained. The application further discloses a method for constructing a GHR humanized rat model by using the CRISPR system, and application of the GHR humanized animal cells and the GHR humanized rat model obtained by the above method in drug screening, drug development or efficacy evaluation. The application can more accurately simulate the interaction between the human GHR and growth hormone and other ligands, improves the accuracy and reliability of research, and has the advantages of simple gene editing operation, high editing efficiency, strong specificity, low off-target effect and wide application range.

The invention relates to two variable spliceosomes of a cynoglossus semilaevis adcyap1b gene and application of the two variable spliceosomes, and belongs to the technical field of functional gene screening and application in the aquatic biotechnology, the two variable spliceosomes are adcyap1b-tv1 and adcyap1b-tv2, coding region CDS sequences of the adcyap1b-tv1 and the adcyap1b-tv2 are SEQ ID NO: 1 and SEQ ID NO: 2, and protein sequences of the adcyap1b-tv2 are SEQ ID NO: 3 and SEQ ID NO: 4. The two variable spliceosomes of the adcyap1b gene are applied to regulation and control of hormone secretion of the pituitary of the cynoglossus semilaevis. By adding the recombinant protein of which the two variable spliceosomes are adcyap1b-tv1 and adcyap1b-tv2 into pituitary cells, the expression of a growth hormone gene gh, a prolactin gene prl, a growth lactin gene sl, a proogonin gene pomc and an adrenocorticotropic hormone release hormone gene crh of the cynoglossus semilaevis is regulated and controlled, so that the growth and development of the cynoglossus semilaevis are influenced.

The present application relates to the technical field of biological medicine, in particular to a long-acting sustained-release human recombinant growth hormone fusion protein, a pharmaceutical composition and application thereof. The growth hormone fusion protein provided by the present application comprises a growth hormone and a temperature-sensitive elastin-like polypeptide. After subcutaneous injection of the fusion protein, phase transition occurs in situ at body temperature, and drug depots are formed. The drug is slowly released from the depots to the body circulation system, significantly prolonging the effective action time of a single injection of growth hormone, improving patient compliance, and improving pharmacokinetic parameters. The growth hormone fusion protein also has significantly improved biological stability and high biological activity, and has excellent application value and potential.

The invention belongs to the technical field of biological medicine and nano-drug delivery, and particularly relates to a long-acting growth hormone (hGH) wrapped bacterial outer membrane vesicle and application, and the outer membrane vesicle GH-OMVs wraps a human growth hormone mutant with an amino acid sequence shown as SEQ ID NO: 1. The GH-OMVs provided by the invention can be used for preparing medicines or preparations for preventing and / or treating diseases related to growth hormone deficiency or growth hormone-related metabolic disorder, including but not limited to growth hormone deficiency, dwarf / low height, osteoporosis and the like, and has a good clinical application prospect.

The present disclosure relates, in general, to methods of treating short stature disorders in a subject who is non-responsive to growth hormone therapy using variants of C-type natriuretic peptide (CNP).

The present invention relates to a long-acting growth hormone or a pharmaceutical formulation comprising such long-acting growth hormone for use in a method of treating growth hormone deficiency with improved outcomes.

The invention relates to the field of biological medicine, and discloses application of an ENPP1 inhibitor in preparation of a medicine for treating pituitary growth hormone adenoma. The ENPP1 inhibitor is a compound with a structure as shown in a formula I, or an isomer, a derivative, a solvate or a pharmaceutically acceptable salt thereof. It is found for the first time that the ENPP1 inhibitor has a remarkable treatment effect on pituitary growth hormone adenoma, not only inhibits secretion of GH, but also inhibits growth of adenoma. Specifically, the inhibitor efficiently inhibits the activity of growth hormone adenoma cells ENPP1, inhibits adenoma cell proliferation and GH secretion in an in-vitro model, reduces the GH and IGF-1 levels of tumor-bearing mice in an in-vivo model, and is suitable for GH adenoma insensitive to somatostatin analogue drugs (such as octreotide). In addition, when the ENPP1 inhibitor is combined with octreotide for use, a synergistic effect is shown, and the anti-tumor effect is further enhanced.

The application belongs to the technical field of biological medicine, and particularly relates to a drug carrier targeting ovaries and a preparation method and application thereof. Specifically, the application provides a drug carrier ZIF-8-GH@ZP3 targeting ovaries, so that targeted treatment for POI is realized, growth hormone is released in a targeted manner to improve the treatment effect and reduce the adverse reactions of growth hormone. The drug carrier is designed by using a zeolite imidazole framework (ZIF-8) and a zona pellucida antibody (ZP3Ab), can release growth hormone in a targeted manner according to different levels of developing follicles in the ovaries, based on the dual functions of targeting and promoting the development of dominant follicles, finally realizes targeted treatment for primary ovarian insufficiency, and has good practical application value.

The invention provides a marker for identifying aggressive behaviors of growth hormone type pituitary tumors and application of the marker, and belongs to the technical field of molecular biology. The marker provided by the invention comprises growth hormone or phosphorylated growth hormone. According to the invention, IGH-PitNETs tissue and plasma GHPs spectrums are drawn by using a 2DE-LC-MS technology, and it is found that specific GHPs exist in IGH-PitNETs. Experiments show that GH, GH-Ser77 phosphorylation and Ser176 phosphorylation are potential invasion biomarkers and treatment targets of GH-PitNETs, and an important theoretical basis is laid for clarification of a growth hormone type pituitary tumor invasion mechanism and development of a new clinical treatment approach.

The present invention provides a fusion polypeptide, the fusion polypeptide targeting both GLP-1 receptors (GLP-1R) and growth hormone receptors (GHR). The present invention provides polynucleotides encoding the fusion polypeptide, vectors expressing the fusion polypeptide and / or comprising the polynucleotides, as well as cells expressing the polynucleotides and / or comprising the vectors. The present invention also provides methods of preparing the fusion polypeptide and use of the fusion polypeptide in the manufacture of a medicament. Also provided are methods of treatment and fusion polypeptides for use in therapy.

This invention relates to the field of biomedical technology, and more particularly to a polypeptide that promotes the release of growth hormone and its applications, said polypeptide being as shown in formula (I). Furthermore, the application of the polypeptide shown in formula (I) in the preparation of medicaments for diagnosing and / or treating diseases related to human growth hormone deficiency is also provided. Formula (I).

This invention discloses a recombinant human growth hormone-collagen fusion protein, its preparation method, and its applications, relating to the field of fusion protein technology. The fusion protein comprises a human growth hormone sequence and a human-like collagen sequence. The amino acid sequence of the fusion protein is shown in SEQ ID NO.7. The first homologous region of the human growth hormone is located at the N-terminus of the fusion protein, and the second homologous region of the human-like collagen is located at the C-terminus. In this invention, recombinant human growth hormone and human collagen with tissue repair function are fused through genetic engineering, achieving efficient expression in the periplasmic space in *E. coli*. High-purity products are obtained by GH affinity chromatography and weak cation exchange chromatography. The protein has a normal structure and good in vitro activity, and can be used to prepare long-acting growth hormone preparations or wound repair materials, showing significant clinical application prospects.

A pituitary adenylate cyclase activating peptide (PACAP) is a neuropeptide associated with a broad range of functions such as nociceptive feelings and primary headache. PACAP is a member of the trypsin / vasoactive intestinal peptide (VIP) / growth hormone releasing hormone (GHRH) family. The present disclosure relates generally to anti-PACAP antibodies, pharmaceutical compositions comprising such antibodies, and methods of producing and using such antibodies.

The invention discloses a cattle growth hormone in-vitro relative biological activity detection method, and belongs to the technical field of biological detection. The method comprises the following steps: construction of pbGHR, construction of HEK293-bGHR-Luc cells, and detection of the in-vitro relative biological activity of the bovine growth hormone. The method disclosed by the invention has the characteristics of low cost, strong stability, strong specificity, high accuracy and precision, simple subsequent operation and short detection time, solves the problem that the relative biological activity of the current cattle growth hormone is not detected at a cellular level, and has a relatively high application value in research and development and quality control of cattle growth hormone drugs.

1. Name of the designed product: needleless injector (2). 2. Use of the designed product: for injecting insulin or growth hormone. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view 1.

Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHD). Also described is a method of treating growth hormone (GH) deficiency (MD) in children with a functional hypothalamic-pituitary GH axis.

Pituitary adenylate cyclase-activating peptide (PACAP) is a neuropeptide involved in a wide range of functions, including nociception and primary headaches. PACAP is a member of the secretin / vasoactive intestinal peptide (VIP) / growth hormone-releasing hormone (GHRH) family. The present disclosure generally relates to anti-PACAP antibodies, pharmaceutical compositions comprising such antibodies, and methods for producing and using such antibodies. For example, the present invention provides an anti-pituitary adenylate cyclase-activating polypeptide (PACAP) antibody, comprising the full-length heavy chain amino acid sequence set forth in SEQ ID NO:1 and the full-length light chain amino acid sequence set forth in SEQ ID NO:2.

The application discloses a bovine growth hormone in vitro relative biological activity detection method and belongs to the technical field of biological detection. The method comprises the following steps: constructing pbGHR, constructing HEK293-bGHR-Luc cells, and detecting bovine growth hormone in vitro relative biological activity. The method has the characteristics of low cost, strong stability, strong specificity, high accuracy and precision, simple subsequent operation, short detection time and the like, solves the problem that bovine growth hormone relative biological activity cannot be detected at the cell level at present, and has high application value in bovine growth hormone drug research and development and quality control.

The invention provides a method for breeding short grain-saving chickens by using a PGC gene editing technology, and belongs to the field of poultry breeding and genetic engineering. A CRISPR-Cas9 system is utilized, gRNA designed for GHR gene 3 'UTR and tenth exon is used for guiding Cas9 nuclease for gene editing, partial deletion is introduced into the chicken GHR gene 3' UTR, the stability or translation efficiency of GHR mRNA is influenced, the expression level of GHR protein is reduced, and partial deletion is introduced into the tenth exon of the GHR gene, so that the intracellular signal transduction function of the GHR protein is damaged. The synergistic effect of the two mechanisms can reduce the sensitivity of the chicken to growth hormone, and the chicken shows the characteristics of being short and small. The short body type is generally related to lower metabolic requirements, and the gene editing chicken bred by the method can maintain the vital activity and production performance with less feed, so that the purpose of saving feed is achieved.

Disclosed herein is a method for manufacturing a recombinant human growth hormone (h GH) modified by a CTP extension in a mammalian cells culture system.

The present application relates to a composition containing growth hormone fusion protein and its use. The composition comprises: growth hormone fusion protein, and at least one of buffer and protective agent; the use of the above composition in the preparation of a medicament for treating and / or preventing diseases related to growth hormone abnormalities. The composition of the present application can reduce or inhibit the generation of molecular fragments, improve the stability of growth hormone fusion protein during preparation and storage; and the composition does not require complex preparation process, can be directly prepared into injection with high stability, and has good long-acting pharmacokinetic characteristics.

The peptide of the present invention has activity for promoting the production of growth hormone (GH) and promoting the growth of the growth plate. Accordingly, the peptide of the present invention can be used for promoting growth and can be effectively used as an active ingredient for the treatment, prevention, or alleviation of growth delay disorders such as short stature.

1. Name of the designed product: needleless injector (1). 2. Use of the designed product: for injecting insulin or growth hormone. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view 1.

The application discloses a method for efficiently expressing sheep growth hormone. The application provides a method for preparing sheep growth hormone, which comprises the following steps: 1) preparing a recombinant vector for expressing sheep growth hormone; the recombinant vector contains a Trx label, a thrombin cleavage site and sheep growth hormone; 2) co-transferring the recombinant vector and a vector for expressing a molecular chaperone into E. coli to obtain a recombinant bacterium for expressing a sheep growth hormone fusion protein; 3) inducing the recombinant bacterium to express the sheep growth hormone to obtain sheep growth hormone with a Trx label; and 4) cleaving the sheep growth hormone with the Trx label by thrombin to obtain sheep growth hormone; the method of the application significantly improves the soluble expression of growth hormone, and the soluble expression of sheep growth hormone is greatly improved by changing expression conditions and co-expressing with a molecular chaperone.

The present invention relates to a long-acting growth hormone (GH) for use in the treatment of an inflammation-induced disease.

The invention relates to a 3 'UTR element, a recombinant vector and a preparation method and application thereof. The inventor selects actin gamma 1 (Actg1) genes, carries out deep analysis and innovative design on 3'UTR of mRNA (messenger ribonucleic acid), and successfully obtains a novel 3 'UTR element (named as an Actg1 element) through systematic screening and functional verification. Compared with a bovine growth hormone poly A signal (bGHpA) which is widely used in the fields of neuroscience research and gene therapy at present, when the Actg1 element is applied to an rAAV vector, the Actg1 element can realize equivalent, efficient and lasting expression with higher cell type specificity in neurons after an exogenous gene is delivered to the brain.